Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 30, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details specific transactions on August 29, 2006, involving the GlaxoSmithKline (US) Trust ("the GSK US Trust") acting on behalf of participants in the GlaxoSmithKline Share Value Plan:
- Sales: The Trust sold 6,480 Ordinary Share ADRs at a price of $55.68 per ADR.
- Transfers: The Trust transferred 13,739 Ordinary Share ADRs to plan participants.
Three directors (Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop) hold interests in the GSK Trust in the same capacity as other employees or former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the aforementioned share transactions in accordance with Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the total volume of ADRs sold (6,480) and transferred (13,739) by the GSK US Trust on August 29, 2006.
- Confirm the transaction price of $55.68 per ADR for the shares sold.
- Note that the transactions were executed on behalf of the GlaxoSmithKline Share Value Plan participants.
- Recognize that the filing does not contain financial results or strategic updates for the company.